OpGen Management

Management criteria checks 0/4

OpGen's CEO is David Lazar, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.79% of the company’s shares, worth $61.30K. The average tenure of the management team and the board of directors is 0.1 years and 0.1 years respectively.

Key information

David Lazar

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.8%
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

CEO

David Lazar (32 yo)

less than a year

Tenure

Mr. David Elliot Lazar is Chairman and CEO of OpGen, Inc. from March 25, 2024. Mr. Lazar serves as Chief Executive Officer, President, Secretary, Chief Financial Officer, Director of UBuyHoldings, Inc. sin...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Oliver Schacht	Executive VP of Corporate Development	less than a year	US$520.80k	0.16% $ 12.2k
David Lazar	CEO & Chairman	less than a year	no data	0.79% $ 61.3k
Vadim Sapiro	Chief Information Officer	12.3yrs	US$311.05k	no data

0.08yrs

Average Tenure

52yo

Average Age

Experienced Management: OPGN's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Lazar	CEO & Chairman	less than a year	no data	0.79% $ 61.3k
David Natan	Director	less than a year	no data	0.79% $ 61.3k
James Snyder	Member of Clinical Advisory Board	no data	no data	no data
Matthew McMurdo	Director	less than a year	no data	0.79% $ 61.3k
Avraham Ben-Tzvi	Director	less than a year	no data	0.79% $ 61.3k
Debra Goff	Member of Clinical Advisory Board	8.1yrs	no data	no data
Stefan Riedel	Member of Clinical Advisory Board	8.1yrs	no data	no data
Patricia Simner	Member of Clinical Advisory Board	no data	no data	no data

0.08yrs

Average Tenure

51yo

Average Age

Experienced Board: OPGN's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.

OpGen Management

Management criteria checks 0/4

Key information

Recent management updates

Opgen, Inc. Announces Executive Changes

High number of new and inexperienced directors

OpGen, Inc., Annual General Meeting, Jun 09, 2022

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021

Recent updates

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. announced that it expects to receive $1 million in funding

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

OpGen to raise $3.38M in direct stock offering

OpGen's subsidiary signs R&D agreement with FIND

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen launches sequencing services for infectious diseases in US

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen reports preliminary revenue estimate for Q2 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen gains on insider buying

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021

OpGen reports prelim Q4 & FY20 revenue

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

OpGen, Inc. Announces Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

OpGen, Inc. announced that it expects to receive $10 million in funding

OpGen launches $10M private placement

OpGen EPS misses by $0.04, beats on revenue

OpGen, Inc. to Report Q3, 2020 Results on Nov 11, 2020

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

OpGen, Inc. Demonstrates the Clinical Utility of Unyvero LRT Panel and Its Potential Impact on Antibiotic Use in Hospitalized Patients with Suspected Pneumonia

OpGen, Inc. Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in Covid-19 Pneumonia Patients and Presents Data on Unyvero Hpn Panel At Eccvid 2020

OpGen, Inc. May File for Bankruptcy

OpGen, Inc. to Report Q2, 2020 Results on Aug 12, 2020

OpGen, Inc. (NasdaqCM:OPGN) completed the acquisition of Curetis AG (“Curetis”) from Curetis N.V. (ENXTAM:CURE).

New 90-day high - US$2.44

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure